NetworkNewsBreaks – Mydecine Innovations Group (
Post# of 160
(Total Views: 193)
Posted On: 12/20/2021 4:11:39 PM
NetworkNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Standing Distinct in Advancing Psychedelic Medicine
Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) recently released financials and a business update for the third quarter ending Sept. 30, 2021. During this reporting period, the company filed three patent applications; successfully synthesized a novel psilocin analogue with improved pharmaceutical properties; launched Mindleap 2.0, an updated version of its proprietary virtual health platform; and completed its spin-out transaction of ALT House Cannabis Inc. “The highlight of this quarter was the five-year research agreement Mydecine Innovations entered with Johns Hopkins University School of Medicine… The agreement gives the company’s medical and scientific research teams the resources needed to explore things like different indications, enhanced delivery, improved dosing, shorter half-life or other improvements needed to advance understanding of these medicines in medical practice,” reads a recent article. “The research agreement is a good indication of the company’s commitment to advancing psychedelic medicine as a whole, since, unlike competitors, they are not just focusing on psilocybin of MDMA. ‘The long-term potential of this research agreement is captivating for use here at Mydecine,’ CSO and Co-Founder Rob Roscow stated. ‘It demonstrates our commitment to advancing psychedelic medicine by exploring multiple molecules and medicines for a variety of indications.’”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) recently released financials and a business update for the third quarter ending Sept. 30, 2021. During this reporting period, the company filed three patent applications; successfully synthesized a novel psilocin analogue with improved pharmaceutical properties; launched Mindleap 2.0, an updated version of its proprietary virtual health platform; and completed its spin-out transaction of ALT House Cannabis Inc. “The highlight of this quarter was the five-year research agreement Mydecine Innovations entered with Johns Hopkins University School of Medicine… The agreement gives the company’s medical and scientific research teams the resources needed to explore things like different indications, enhanced delivery, improved dosing, shorter half-life or other improvements needed to advance understanding of these medicines in medical practice,” reads a recent article. “The research agreement is a good indication of the company’s commitment to advancing psychedelic medicine as a whole, since, unlike competitors, they are not just focusing on psilocybin of MDMA. ‘The long-term potential of this research agreement is captivating for use here at Mydecine,’ CSO and Co-Founder Rob Roscow stated. ‘It demonstrates our commitment to advancing psychedelic medicine by exploring multiple molecules and medicines for a variety of indications.’”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Mydecine Innovations Group Inc (MYCOF) Stock Research Links
Scroll down for more posts ▼